Zevra Therapeutics (NASDAQ:ZVRA) PT Raised to $18.00 at HC Wainwright

Zevra Therapeutics (NASDAQ:ZVRA) had its target price lifted by HC Wainwright from $15.00 to $18.00 in a research report sent to investors on Monday morning, Benzinga reports. HC Wainwright currently has a buy rating on the stock. HC Wainwright also issued estimates for Zevra Therapeutics’ FY2025 earnings at $0.26 EPS and FY2028 earnings at $3.12 EPS.

Zevra Therapeutics Stock Performance

Shares of NASDAQ:ZVRA remained flat at $7.88 during mid-day trading on Monday. 1,443,028 shares of the stock were exchanged, compared to its average volume of 376,750. The firm has a market cap of $329.80 million, a price-to-earnings ratio of -5.92 and a beta of 1.97. The firm’s fifty day simple moving average is $5.19 and its two-hundred day simple moving average is $5.43. The company has a quick ratio of 2.10, a current ratio of 2.10 and a debt-to-equity ratio of 0.88. Zevra Therapeutics has a 52 week low of $3.89 and a 52 week high of $8.44.

Zevra Therapeutics (NASDAQ:ZVRA) last issued its quarterly earnings results on Wednesday, May 8th. The company reported ($0.40) EPS for the quarter, topping analysts’ consensus estimates of ($0.49) by $0.09. The company had revenue of $3.43 million for the quarter, compared to analyst estimates of $3.52 million. Zevra Therapeutics had a negative net margin of 181.76% and a negative return on equity of 82.55%. Analysts predict that Zevra Therapeutics will post -1.57 EPS for the current fiscal year.

Insider Activity at Zevra Therapeutics

In other news, Director Thomas Anderson bought 10,000 shares of the company’s stock in a transaction that occurred on Tuesday, July 16th. The shares were acquired at an average price of $6.81 per share, for a total transaction of $68,100.00. Following the completion of the acquisition, the director now directly owns 20,000 shares in the company, valued at $136,200. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Insiders have bought a total of 22,000 shares of company stock worth $140,340 over the last quarter. Company insiders own 2.40% of the company’s stock.

Institutional Investors Weigh In On Zevra Therapeutics

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Jump Financial LLC bought a new stake in Zevra Therapeutics in the fourth quarter valued at $217,000. Armistice Capital LLC bought a new stake in Zevra Therapeutics in the fourth quarter valued at $1,755,000. Jacobs Levy Equity Management Inc. increased its stake in Zevra Therapeutics by 102.4% in the first quarter. Jacobs Levy Equity Management Inc. now owns 34,707 shares of the company’s stock valued at $201,000 after purchasing an additional 17,557 shares in the last quarter. SG Americas Securities LLC increased its stake in Zevra Therapeutics by 41.7% in the fourth quarter. SG Americas Securities LLC now owns 20,999 shares of the company’s stock valued at $138,000 after purchasing an additional 6,175 shares in the last quarter. Finally, Virtu Financial LLC bought a new stake in Zevra Therapeutics in the fourth quarter valued at $177,000. 35.03% of the stock is owned by institutional investors.

About Zevra Therapeutics

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy.